The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

NATICK, Mass., European regulators have approved an expanded indication for the Boston Scientific Corporation WATCHMAN ® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients ...

Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

Procedures to implant the WATCHMAN left atrial occlusion device had a high implant success rate and a low rate of in-hospital complications in an analysis of more than 38,000 procedures presented at ...

With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE:BSX) ranks among the top 10 ...

Atrial fibrillation is a condition that affects a large number of the population, causing fatigue, shortness of breath, heart palpitations and could eventually lead to stroke. Mercy Health has a safer ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing a transcatheter aortic valve replacement (TAVR) at the same time as a left atrial appendage ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation MARLBOROUGH, Mass., Boston Scientific Corporation has received U ...

Atrial fibrillation (AF) is an increasingly common heart rhythm disorder that affects approximately 59 million people worldwide 1 and increases stroke risk by five times compared to people with a ...